Solar urticaria

Summary

Solar urticaria (MONDO:0019945) is a disease and 4 clinical trials. Top therapeutic interventions include afamelanotide, omalizumab, and titanium dioxide. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 16
• Clinical trials: 4

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000	3.1	United Kingdom	Validated

Signs & symptoms

Clinical features (HPO)

16 HPO clinical features (Orphanet curated; top 16 by frequency):

HPO ID	Term	Frequency
HP:0000159	Abnormal lip morphology	Very frequent (80-99%)
HP:0000969	Edema	Very frequent (80-99%)
HP:0000989	Pruritus	Very frequent (80-99%)
HP:0001025	Urticaria	Very frequent (80-99%)
HP:0001279	Syncope	Very frequent (80-99%)
HP:0002018	Nausea	Very frequent (80-99%)
HP:0002315	Headache	Very frequent (80-99%)
HP:0002321	Vertigo	Very frequent (80-99%)
HP:0030809	Abnormal tongue morphology	Very frequent (80-99%)
HP:0030828	Wheezing	Very frequent (80-99%)
HP:0100326	Immunologic hypersensitivity	Very frequent (80-99%)
HP:0100539	Periorbital edema	Very frequent (80-99%)
HP:0100665	Angioedema	Very frequent (80-99%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0011971	Dermatographic urticaria	Occasional (5-29%)
HP:0100845	Anaphylactic shock	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	solar urticaria
Mondo ID	MONDO:0019945
Orphanet	97230
ICD-10-CM	L56.3
ICD-11	64163683
SNOMED CT	10347006
UMLS	C0263610
MedGen	538004
GARD	0019353
MedDRA	10041307
Is cancer (heuristic)	no

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › solar urticaria

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00483496	PHASE2	COMPLETED	Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
NCT00859534	PHASE2	COMPLETED	Phase II Solar Urticaria (SU) Pilot Study
NCT01360658	PHASE2	COMPLETED	Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
NCT02262130	PHASE2	COMPLETED	Omalizumab in Severe and Refractory Solar Urticaria

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AFAMELANOTIDE	4	1
OMALIZUMAB	4	1
TITANIUM DIOXIDE	4	1
BISOCTRIZOLE	2	1